Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 21,035 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immune System Disorders Clear all

Conditions: Asthma in Children
Interventions: Inhaled corticosteroid (mometasone); Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 8 Years to 20 Years
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Rocky Mountain MS Research Group, LLC; Other
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Seasonal Allergic Rhinitis
Interventions: Bepotastine besilate formulation, Fluticasone propionate, Bepotastine besilate-fluticasone propionate, Placebo Comparator; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Irvine, California

Conditions: Asthma
Interventions: Vitamin E supplement rich in gamma tocopherol; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Rheumatoid Arthritis, Cardiovascular Disease
Interventions: Not listed
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Sjögren's Disease
Interventions: DDY391, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Avondale, Arizona • Clearwater, Florida • Tampa, Florida + 9 more

Conditions: Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Myasthenia Gravis, Muscle Weakness
Interventions: anito-cel, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 10 more

Conditions: Diabetes, Autoimmune
Interventions: DiaPep277; Drug
Lead sponsor: DeveloGen Israel, Ltd.; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 7
States / cities: Birmingham, Alabama • Aurora, Colorado • Lexington, Kentucky + 4 more

Conditions: Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Asthma
Interventions: Dose 4 QD, Dose 3 QD, placebo, Dose 2 QD, Dose 1 BD; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Cypress, California • Huntington Beach, California • Bethesda, Maryland + 6 more

Conditions: COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions: vaccinated; Biological
Lead sponsor: Neuroganics LLC; Industry
Eligibility: 5 Years to 99 Years
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Northglenn, Colorado

Conditions: Arthritis, Rheumatoid, Medication Adherence
Interventions: Motion sensors and daily online assessments; Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Psoriasis, Atopic Dermatitis
Interventions: Pandel Cream 0.1%; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 3 Months and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 3
States / cities: Omaha, Nebraska • Hilton Head Island, South Carolina • Nashville, Tennessee

Conditions: Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
Interventions: Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil; Drug
Lead sponsor: University of Utah; Other
Eligibility: Up to 21 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Psoriasis
Interventions: Calcipotriene 0.005% Foam; Drug
Lead sponsor: Mayne Pharma International Pty Ltd; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 36
States / cities: Birmingham, Alabama • Rogers, Arkansas • Encino, California + 30 more

Conditions: Follicular Lymphoma, Tumor
Interventions: Obinutuzumab, CC-99282; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Interventions: dasatinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 26
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 21 more

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: Dolastatin 10; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia
Interventions: alemtuzumab, fludarabine phosphate; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 50
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 31 more

Conditions: Diffuse Large Cell Lymphoma, Burkitt's Lymphoma, High Grade B-cell Lymphoma
Interventions: Rituximab, IT Cytarabine; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 3 Years to 31 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 5
States / cities: Buffalo, New York • Valhalla, New York • Charlotte, North Carolina + 2 more

Conditions: Multiple Myeloma, Lymphoma
Interventions: Busulfan, Melphalan; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: X-linked Severe Combined Immunodeficiency, X-SCID, XSCID
Interventions: Plerixafor, Filgrastim, Palifermin, Busulfan, Base-edited hematopoietic stem and progenitor cells; Genetic · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 99 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: 7-hydroxystaurosporine, prednisone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 3
States / cities: Bethesda, Maryland • Frederick, Maryland

Conditions: Leukemia
Interventions: Arsenic Trioxide; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Tampa, Florida

Search by objective public record fields.

Stress and Treatment Response in Puerto Rican Children With Asthma

Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk

Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

Safety Study of a Vitamin E Supplement in Normal Volunteers and Those With Both Allergy and Asthma

Low Density Lipoprotein Cholesterol (CLDL) as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis

A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases

Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)

Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies

Efficacy and Safety Study in Subjects With Asthma

National Vaccine Adverse Event Reporting Survey and Etiology

Wireless Motion Sensors for Rheumatoid Arthritis Patients - Pilot Study

Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Treatment for Advanced B-Cell Lymphoma

Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma

Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma

Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia